Galapagos receives Fast Track designation from FDA

12:20 EST 28 Nov 2018 | Investing News Network

Galapagos (Euronext & NASDAQ:GLPG) announced today that the FDA has granted GLPG1972/S201086 Fast Track designation for the treatment of patients with osteoarthritis (OA). As quoted in the press release: The US Food and Drug Administration’s (FDA’s) Fast Track program is designed to facilitate the development and expedite the review of drugs that treat serious or life-threatening … Continued

The post Galapagos receives Fast Track designation from FDA appeared first on Investing News Network.

Original Article: Galapagos receives Fast Track designation from FDA


More From BioPortfolio on "Galapagos receives Fast Track designation from FDA"

Quick Search


Relevant Topics

Arthritis is by definition the inflammation of one or more joints, characterized by swelling, pain, warmth, redness and diminished range of joint movement (Oxford Medical Dictionary). There are many different types; Noninflammatory; Osteoarthritis, N...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...